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A R T I C L E I N F O A B S T R A C T
Background: Coronary artery disease is the leading cause of illness and death in older adults. Around 40% to 50% 
of patients with ST-segment elevation myocardial infarction (STEMI) have multiple coronary artery disease. 
Multiple vessel coronary disease has been shown to improve cardiac outcomes and survival in patients who have 
undergone complete revascularization (CR) versus patients who have undergone only incomplete revasculariza-
tion (ICR). 
Objective: In this review, we discussed the benefit of complete revascularization in acute coronary syndrome 
(ACS) patients with multivessel disease and which patient can be performed aggressive revascularization to 
achieved CR in clinical practice.
Discussion: When coronary angiography and PCI of the source of the infarction are performed on patients with 
ACS, the risk of adverse cardiac death or myocardial infarction is significantly reduced. Additional research is 
needed to determine the efficacy of PCI in non-critical lesions. However, following procedures such as CABG or 
PCI, these procedures may be impossible to perform due to a variety of personal, anatomical, technical, and 
logistical barriers. 
Conclusion: In order to make a clinical decisions, lesions need to be evaluated as well as several variables, such as 
patient behavior, cardiovascular health, and other factors also have to be considered. CR has been demonstrated 
in several studies to result in decreased rehospitalization and the need for repeated revascularization in the 
subsequent period in ACS patients with a low SYNTAX score and no cardiogenic shock.
Keywords:
Complete Revascularization; 
Acute Coronary Syndrome; 
Percutaneous Coronary Intervention
 
 About half of patients with STEMI and two-thirds of patients 
with non–ST-segment elevation acute coronary syndromes (NSTEACS) 
have additional stenosis distal to the infarct-related artery. Additional 
non-culprit revascularization may be possible in patients with acute 
coronary syndromes (ACS) and multivessel disease.1 A worse 
short-term and long-term prognosis has occurred with multivessel 
coronary disease (MVD). Some lesions indicate a stable plaque of 
atherosclerosis, which may exclude invasive treatment. An unstable, 
fragile plaque with high-risk characteristics suggests other lesions, 
indicating an increased risk of further cardiovascular events.2
 Cardiogenic shock exacerbates the mortality associated with 
acute myocardial infarction when prompt revascularization, including 
percutaneous coronary intervention, is performed (AMI). It remains 
between 40% and 60%. Additionally, patients over the age of 75 with 
AMI complicated by cardiogenic shock may have higher one-year 
mortality than their younger counterparts, regardless of age or gender.
About 34%–50% of patients with STEMI have multiple vessel coronary 
artery disease.3 For several decades, the ideal strategy for MVD revascu-
larization in the setting of STEMI has been a topic of research and 
debate. Numerous solutions have been suggested, including the follow-
ing: (a) Culprit-only revascularization (COR) with subsequent revascu-
larization based on symptoms or non-invasive imaging proof of 
ischemia, (b) Complete revascularization (CR) at the time of the index 
culprit-lesion procedure, or (c) Complete revascularization as a staged 
procedure either concurrently with or shortly after the index culprit 
lesion procedure (within 45 days).2
 While complete revascularization was not an independent 
predictor of mortality in the general population, it was associated with 
a lower risk of death in patients with chronic lung disease, a history of 
congestive heart failure, or who had not previously received PCI. 
Although this research was not intended to assess if full revasculariza-
tion is superior to partial revascularization, the results indicate that 
when PCI is used to treat patients with coronary artery disease, achiev-
ing complete revascularization does not result in an increased risk of
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death. 4 However, the relative benefits of full revascularization of both 
culprit and non-culprit vessels versus culprit-only or partial revascular-
ization continue to be discussed around the spectrum of acute coronary 
syndromes treated with percutaneous coronary intervention (PCI). One 
obvious benefit of incomplete revascularization is that it treats ruptured 
or eroded plaque while preventing periprocedural complications associ-
ated with a non-culprit intervention. By contrast, as shown recently in 
STEMI, full revascularization may affect potential cardiac events.5
 We discussed a new paradigm for treating ACS patients with 
multivessel disease in this review article. This subject has been widely 
discussed in recent years, and there are numerous contradictory data. 
We discussed which patients benefited more from complete revascular-
ization or culprit-only revascularization.
2. Discussion
2.1 Culprit Only Revascularization in STEMI
 Various retrospective trials and registry-based studies 
supported the superiority of culprit-only revascularization for ST-seg-
ment elevation myocardial infarction. Although Cavendor et al. found 
that CR (with survival at the hospital) was associated with a significant-
ly higher risk of mortality (7.9% vs 5.1%, p=0.01), Both three random-
ized clinical trials and eight thousand patients in total (CR, 7,498 
patients; COR, 8,240) were included in the data review by Dr. Lu, along 
with non-randomized studies (N = 10,999) that additionally included 
6,997 subjects undergoing CR and 7,509 subjects undergoing CABG 
(COR). creativity is linked to an increased risk of death and kidney 
disease.7 
 
When Iqbar and colleagues surveyed 3,804 patients with MVD who had 
PCI done at tertiary hospitals in London between 2004 and 2011, they 
found similar results. There was a decrease in the number of in-hospital 
significant incidence of major adverse cardiac events and mortality 
which was associated with the COR strategy at one year. Moreover, the 
observational results indicated a significant reductions in in the chances 
of both MACE (OR 0.49; 95% confidence interval, 0.32–0.91; 
p<0.001) and 1-year survival (out of hospital MACE: 0.47; 95% CI, 
0.32–0.91; p=0.011) in the entire cohort, and an expanded propensity 
matching group (OR 0.49; 95% CI, 0.32–0.91; OR 0.91) for MACE) 
This result was borne out by inverse likelihood treatments, which 
revealed that COR was a key independent risk factor for MACE (OR, 
0.38; 95% confidence interval, 0.15–0.96; odds ratio, 0.35 to 1.44) and 
survival (HR, 0.33; 95% confidence interval, 0.21 to 0.45 to 0.44) over 
a year after an episode of AMI.)8
 Recent results have supported the 2013 American College of 
Cardiology/AHA STEMI Guidelines.9 It has also been used to help 
patients with cardiogenic shock or refractory periods who do not have 
creatinine phosphokinase (CPK) elevations (CPI). However, the ESC 
also recommended non-culprit revascularization in patients who are 
shocked, or who have critical lession following PCCI when other culprit 
causes cannot be identified, or who are not improving after PCI (IIb).10
 In patients with acute myocardial infarction with cardiogenic 
shock, the early PCI revascularization of the culprit artery will increase 
the survival rate. However, a majority of cardiogenic shock patients 
have multivessel disorder and whether PCI should be performed in
stenoses in non-culprit arteries immediately is problematic. In the 
CULPRIT SHOCK trial, one of two initial revascularization strategies 
has been randomly allocated to 706 patients suffering from a multives-
sel, acute myocard infarction, and a cardiogenic shock: culprit lesion 
PCI alone with the option of staged revascularization of the non-culprit 
lesion or immediate multi-vessel PCI. In patients with a MVD and an 
acute cardiogenic myocardial infarction who initially suffered a PCI 
from the culprit lesion, the 30-day risk of having a composite death or 
severe renal failure requiring renal substitution was lower than for 
those who were immediately affected by multi-vessel PCI.11
2.2 Complete Revascularization in STEMI
 There is considerable debate about the optimal treatment 
strategy for patients with STEMI, cardiogenic shock, who exhibit 
multivessel disease on initial coronary angiography. There is disagree-
ment about whether to revascularize the culprit only or the whole 
vessel during the index revascularization, and the appropriate 
approach needs to be re-addressed. Cardiogenic shock, which occurs in 
the presence of prompt revascularization, including percutaneous 
coronary intervention, exacerbates the mortality associated with AMI. 
It remains between 40% and 60%. Additionally, in terms of age and 
gender, patients over the age of 75 with AMI complicated by 
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Figure 1. Odds ratios for mortality associated with multivessel PCI in a 2009 study by Cavender et al. Even after adjustment for confounding variables, patients in 
cardiogenic shock treated with multivessel PCI had an increased risk of death compared to patients treated with PCI of the infarct-related artery alone. Patients who 
were not in cardiogenic shock demonstrated a non-significant trend toward an increased risk of death.6
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cardiogenic shock can have higher one-year mortality than their young-
er counterparts. About 34%–50% of patients with STEMI have coronary 
artery disease involving multiple vessels.13
 In several clinical trials published in recent years, there have 
been doubts as to the optimal revascularization strategy for STEMI 
patients with multivessel heart disease, which lays the foundations for 
a change in our understanding of the paradigm. In 2013, the PRAMI 
trial findings were presented in a paper by Wald et al. In the case of 
STEMI and MVD, 465 patients received primary PCI. Patients have 
been randomly assigned to undergo either complete PCI with 234 
patients or COR with 231 patients. The main result was a combination 
of cardiac death, non-fatal myocardial infarction, and angina. After a 
median follow-up of 23 months, the analysis was completed early due 
to a significantly improved primary CR performance. It was the result 
of a reduction in the likelihood of repeated revascularization (6.8% 
versus 19.9%), nonfatal MI (3.5% versus 8.7%), and refractive angina 
(5.1 percent vs 13.0 percent). In addition, the trend to decrease heart 
mortality with a hazard ratio of 0.34 has also been important. Further-
more, the average of all major cardiac death endpoints and non-fatal 
MI decreased significantly with a risk of 0.36.14
 After around two years, the Randomized Trial of Complete 
vs. Lesion-Only Revascularization in Patients Undergoing Primary 
Percutaneous Coronary Intervention for STEMI or Multi-Vessel Disease 
(The CvLPRIT Trial). That was conducted at seven hospitals in the U.K. 
hospitals and enrolled a total of 296 STEMI patients. Complete revascu-
larization was done either concurrently with primary PCI or in stages 
prior to hospital discharge stratification was used in order to stratify by 
time of onset and location of infarction. Survival rate of any cause 
mortality, chronic MI, heart failure, and MI related procedure of 
revazcularization were the primary measures of the study's efficacy. 
The primary outcome occurred in 10% of the CR population, compared 
to 21.2% of the COR group (hazard ratio: 0.24; CI: 0.13-0.44; p = 
0.009), which was later concluded to be due to less angina events and 
more effective treatment of ischemia-mediated vessels and the risk of 
which is significantly lowered. Although there was no evidence of any 
real change in mortality or myocardial infarction, the study found a 
substantial. It should be noted that there was no significant difference 
in the severity of any bleeding, contrast-induced nephropathy, or stroke 
between groups.15
 Physiologic severity of lesion was not considered in the 
PRAMI and CVLPRIT trials. The DANAMI-3PRIMULTI Trial and 
COMPASS trials were revolutionary in their use of the factional flow 
reserve (FFR). There is evidence to show that the FFR is an effective 
way to evaluate non-culprit lesion in patients with multiple-vessel 
AMI.16 Study that analyzed 627 STEMI patients were included in the 
DANAMI-3-PRIMULTI Trial who had at least one other significant 
coronary artery lesion. Patients were divided into two groups: those in 
whom PCI plus FFR revascularization prior to discharge and those in 
whom no further care was indicated. The research objectives included 
evaluating the association between primary out-outcome measures of 
reinfarction, nonfatal infarction, and revascularization of non culprit 
related arteries. Complete revascularization led by FFR measurements 
was performed a median of two days after  initial PCI procedure. Prima-
ry endpoint was achieved in 68 (22%) patients assigned to the COR 
group and 40 (13%) patients assigned to the CR group with hazard
ratio 0.56. According to the current findings, again CR had beneficial 
effect due to its impact on ischemia-induced revascularization (CI: 
0.18-0.53; HR: p < 0.001).17
 The COMPARE-ACUTE study target-guided PCI to those who 
used FFR or COR in 885 patients with multivessel disease who received 
primary PCI of a vessel-related target. Unlike the DANAMI-3-PRIMULTI 
Trial, both groups underwent the FFR procedure during primary PCI to 
avoid the need for sequential catheterizations and to save money. The 
design of the study did not enable the patients and their cardiologists to 
know the relative frequency of positive and negative FFR outcomes to 
be compared, eliminating the possibility of confounding biases. By the 
year mark, the primary endpoint was catastrophic MI, nonfatal MI, and 
cerebrovascular event. CR as found in earlier trials to be mainly due to 
a decline in subsequent revascularizations.18
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Figure 2. Primary Outcome from PAMI study. The primary result was a cardiac death composite, non-fatal myocardial infarction, or angina refractory. All patients 
in the study were randomized immediately before infarction-artery PCI.14
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 From the outcomes of four clinical trials, it was decided that 
CR and COR had better results on average (PRAMI, CvLPRIT, 
COMPARE, and DANAMI-3-PRIMULTI). The American College of 
Cardiology, American Heart Association, and SCAI upgrade their 
approach to primary percutaneous coronary intervention in 2013 from 
class III to class IIb in the following year. According to the revised 
guidelines, complete revascularization may be considered either as part 
of the primary percutaneous coronary intervention or in a subsequent 
staged procedure. According to these recommendations, multivessel 
procedures should be applied to all patients with STEMI in 2017 ESC 
guideline.20
2.3 Complete Revascularization in NSTEACS
 Bainey et al. showed that complete revascularization occurs 
regularly and is associated with improved clinical results, through a 
detailed prospective angiography-based registry of ACS patients under-
going PCI. A 10% (risk-myocardium) residual angiographical risks 
score was correlated with a decreased death risk from any new cause or 
MI within five years. In addition, after complete revascularization, this 
study showed a drop in total mortality. Incomplete revascularization, 
on the contrary, has increased the adverse effects proportionally to the 
amount of myocardium affected. The full renewal was correlated with 
a decrease of 22 percent in the composite of death or recurrent MI over 
the long-term following adjustment for confusing variables. Compara-
ble death and MI reductions have also been found alone. The benefits 
of complete revascularization are also almost definitely related to the 
treatment of non-cultural lesions as a preventive step to reduce 
long-term risk.21
 Total revascularization, irrespective of the type of ACS 
presentation, was correlated with better clinical results within five 
years. There are no randomized trials to support complete revascular-
ization of multivessel PCI-patients with NSTEACS. In an ACUITY 
research (ACUITY) study, a rise in the probability of mortality, MI, or 
unplanned revascularization and the trend towards increased death 
was correlated with incomplete revascularization. The multivessel PCI 
was associated with a decrease in death or recurring MI or revascular-
ization over 2-year median follow-up in a small retrospective study 
conducted in 1240 NSTEACS patients.22
 The advantage of using FFR to guide PCI in dysfunctional 
angina/NSTEMI population is comparable with the stable angina 
population, as seen for the first time in a FAME report. The use of FFR, 
including NSTEMI's culprit lesion, was subsequently demonstrated to 
be feasible and secure in a randomized controlled trial setting.23 The 
expected time frame of non-culprit lesion PCI was fixed for randomiza-
tion in the COMPLETE trial. Prior to the randomization, investigators 
had to find out, whether during the index hospitalization or after 
discharge (within 45 days) they needed to perform PCI for non-culprit 
lesions whether the patient was allocated to a whole population of 
revascularization. This study found that complete revascularization is 
clearly advantageous, irrespective of whether the lesion was not the 
culprit. PCI was performed immediately or several weeks later follow-
ing index hospitalization.5
2.4 Complete Revascularization in Specific Population 
 Chronic kidney disease (CKD) is rising in prevalence among 
PCI candidates, owing to the aging population and the growing burden 
of comorbidities such as diabetes mellitus. Additionally, since patients 
with chronic kidney disease have more severe and complex coronary 
lesions than patients with retained renal function, CKD has been 
identified as a significant indicator of adverse cardiovascular events 
following PCI. A trial was conducted to determine the therapeutic 
utility of angiographic full revascularization with contemporary stents 
in a population of patients with chronic kidney disease by using the 
Grand Drug-Eluting Stent registry in Korea. The findings demonstrate 
that angiographic complete revascularization resulted in improved 
clinical outcomes in patients with chronic kidney disease (CKD) and
outcomes. This finding was consistent with a sub-study of the SYNTAX 
trial, which demonstrated that a residual SYNTAX score of less than 8 
was associated with comparable 5-year mortality following full 
revascularization. However, a residual SYNTAX score of 3 was a fair 
degree of revascularization in patients with chronic kidney disease. 
While we were unable to determine a definitive degree of appropriate 
incomplete revascularization using registry data, our findings indicate 
that we should treat residual disease more carefully in patients with 
CKD and that efforts to achieve complete revascularization are more 
critical in patients with CKD than in patients with preserved renal 
function.25
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Figure 3. Result of trial that showed benefit of CR in STEMI with guidance of FFR. (A) COMPLETE-ACUTE trial showed CR significantly improved survival than 
COR in first year18 (B) DANAMI-3 PRIMULTI trial showed reduced event rate in patient that performed complete revascularization.17
(A) (B)
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 Around 40% of patients with a one permanent chronic 
occlusion (CTO) also have diabetes melitus (DM). In exchange, DM is 
associated with an increased CTO risk. Although successful CTO renew-
al in patients with diabetes tends to be associated with better clinical 
outcomes, there is no evidence that this high-risk population has an 
appropriate choice of care. Coronary artery graft bypass (CABG) is the 
recommended form of revascularisation in multi-vessel patients with 
diabetes mellitus (DM). In addition to single medicamentosa 
treatment, the effective PCI of CTO is associated with lower long-term 
mortality rates. The CABG group experiences complete revasculariza-
tion more frequently than the PCI group (62 percent vs. 32 percent). 
Multivariable research found that the rates of all-cause CABG and 
cardiac mortality in relation to PCI were correlated with substantially 
lower. The effective PCI CTO procedure has been correlated with an 
all-cause mortality trend.26
2.5 Cost Benefit of Complete Revascularization
 The leading cause of death and major worldwide burden in 
Indonesia is cardiovascular disease, with more than 150 000 deaths per 
year, and annual costs in the United Kingdom of over £15 billion.27 The 
cost of a PCI procedure was RM11 471 (US$ 3186) to RM14 465 (USD 
4018) in Malaysia, and over half the total cost of PCI consumables. As 
shown in this cross-sectional study, alternative procurement practices 
for PCI consumables could lead to cost savings. Economic analysis can 
be performed with a costing approach adapted to the context of the 
country for countries with limited access to data.28
 Although these results are confirmed in larger studies, 
emerging clinical studies make a cost-effectiveness assessment of 
overall against infarct-only revascularisation. Although there may be 
increased upfront costs associated with revascularization, it is import-
ant that we understand whether these costs are covered by lower future 
hospital admissions and less adverse events. CvLPRIT research has 
shown that complete revascularization during index admission has 
been more effective in terms of fewer major adverse cardiovascular 
events and an increase in QALY gain than IRA-only revascularisation in 
a population of STEMI patients and multivessel diseases. Since higher 
procedural costs are generally compensated for by lower re-admission 
rates, implying comparable total costs, these data show that complete 
revascularization is an economical way to treat STEMI and multivessel 
patients.27
 Between 2005 and 2015, a CAD epidemic costs the Govern-
ment of India 237 million US dollars (USD) reported by the World 
Health Organization (WHO). The use of an FFR-guided approach in the 
treatment of SIHD patients demonstrated substantial cost savings both 
in private and public health in Asia-Pacific countries. The evaluation of 
FFR by Thomson et al. has found that 80 percent of patients have 
changed their management strategy. In almost one-third of patients 
referred for coronary PCI, only 29% of surveyed lesions were hemody-
namically significant, resulting in stent avoidance. In countries where 
most of the patients self-support their health care, the PCI is convenient 
and cost-effective with almost one in three coronary angioplasty 
patients refusing stent and PCI.28 The subsequent report from the 
COMPARE-ACUTE trial would examine the outcome after three years, 
as well as the cost of this technique. After 36 months, the primary 
outcome (death, myocardial infarction, revascularization, and stroke) 
occurred substantially less frequently in the FFR-guided complete 
revascularization group: 46/295 patients (15.6 percent) versus 
178/590 patients (30.2 percent) (HR 0.46, 95 percent confidence 
interval [CI]: 0.33-0.64; p0.001). This advantage was primarily due to 
a decrease in revascularizations during the follow-up period (12.5 
percent vs 25.2 percent; HR 0.45, 95% CI: 0.31-0.64; p0.001). Cost 
analysis demonstrates the utility of the FFR-guided complete revascu-
larization approach, which can reduce costs per patient by up to 21% in 
the first year (8,150€ vs 10,319€) and by 22% in the second year 
(8,653€ vs 11,100€).19
3. Conclusion
 Due to advances in the optimal treatment of STEMI, the 
strategy for revascularization has progressed over the years. In order to 
make a clinical decisions, lesions need to be evaluated as well as several 
variables, such as patient behavior, cardiovascular health, and other 
factors also have to be considered. in STEMI patients with a low 
SYNTAX score and no cardiogenic shock, CR should be pursued. This 
can be attempted either simultaneously with the admission or after the 
discharge of the patient from the hospital within 45 days. CS and 
non-IRA CTO patients respond best to a COR approach. While some 
clinical trials used angiographic guidance alone, FFR-guided revascu-
larization can be used to make decisions on which non-culprit lesions to 
treat. In some specific conditions associated with the patient, such as 
chronic kidney disease (CKD) or diabetes, choosing a fair partial 
revascularization is still permissible if complete revascularization is not 
possible. The cost effectiveness of CR has been demonstrated in several 
9
Figure 4. Cumulative incidence of clinical outcomes after complete and incomplete revascularization in patient with CKD.24
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variables, such as patient behavior, cardiovascular health, and other 
factors also have to be considered. in STEMI patients with a low 
SYNTAX score and no cardiogenic shock, CR should be pursued. This 
can be attempted either simultaneously with the admission or after the 
discharge of the patient from the hospital within 45 days. CS and 
non-IRA CTO patients respond best to a COR approach. While some 
clinical trials used angiographic guidance alone, FFR-guided revascu-
larization can be used to make decisions on which non-culprit lesions to 
treat. In some specific conditions associated with the patient, such as 
chronic kidney disease (CKD) or diabetes, choosing a fair partial 
revascularization is still permissible if complete revascularization is not 
possible. The cost effectiveness of CR has been demonstrated in several 
studies to result in decreased rehospitalization and the need for repeat-
ed revascularization in the subsequent period.  
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